Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
Rhythm Pharmaceuticals (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of a new non-interventional patient registry, called Tracing the Effect of the MC4R Pathway in Obesity(TEMPO). The TEMPO registry protocol is being presented at the 57th Annual European Society for … Continued
Rhythm Pharmaceuticals (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of a new non-interventional patient registry, called Tracing the Effect of the MC4R Pathway in Obesity(TEMPO). The TEMPO registry protocol is being presented at the 57th Annual European Society for Paediatric Endocrinology (ESPE) Meeting held September 27-29, 2018 in Athens, Greece.
As quoted in the press release:
“We are pleased to announce the launch of the TEMPO registry, a landmark effort to gather clinical information about people affected by rare genetic disorders that lead to insatiable hunger and severe obesity,” said Keith Gottesdiener, M.D., Chief Executive Officer of Rhythm. “This registry will support global efforts to measure the prevalence of these disorders and collect data on the burden of disease. Data from the registry will also help inform future research aimed at identifying effective strategies to improve patient care and management in the years ahead.”
The TEMPO registry is open to patients two years of age and older who present with severe obesity early in childhood and may experience insatiable hunger, also known as hyperphagia. Potential patients can be referred to coordinating centers by their healthcare provider, whether a treating physician, diagnosing physician or primary care physician, and must meet certain eligibility criteria. The registry will capture data entered by the patient as well as healthcare providers and caregivers using online survey tools administered at baseline and annually thereafter. Survey tools include questions on patient and caregiver demographics, physical activity, food and hunger episodes, quality of life, and caregiver perspective of burden of disease on the family.
